Runben Biotechnology Co., Ltd. (SHA:603193)

Runben Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	171.93	185.77	106.59	243.83	368.21	206.19
Short-Term Investments	-	292.94	77.95	1,340	-	-
Trading Asset Securities	1,338	990.17	1,249	19	8.24	56.24
Cash & Short-Term Investments	1,510	1,469	1,434	1,603	376.45	262.43
Cash Growth	6.17%	2.46%	-10.57%	325.85%	43.45%	221.20%
Accounts Receivable	93.22	17.91	13.59	4.82	1.19	2.34
Other Receivables	6.6	4.3	4.62	2.32	6	9.8
Receivables	99.83	22.22	18.22	7.14	7.2	12.15
Inventory	161.41	120.59	118.57	92.91	102.71	56.9
Other Current Assets	23.71	28.33	24.43	13.16	23.68	12.89
Total Current Assets	1,795	1,640	1,595	1,716	510.04	344.36
Property, Plant & Equipment	343.12	295.88	267.57	260.42	277.56	207.67
Other Intangible Assets	86.28	87.32	54.54	18.76	19.36	19.88
Long-Term Deferred Tax Assets	60.95	50.43	44.23	20.82	14.8	5.66
Long-Term Deferred Charges	1.99	1.51	1.26	1.41	-	-
Other Long-Term Assets	262.48	262.61	256.9	1.13	3.65	68.77
Total Assets	2,550	2,338	2,219	2,019	825.42	646.34

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	124.45	-	-	40.15	36.99	46.37
Accrued Expenses	37.24	36.27	32.16	26.21	24.43	11.41
Current Portion of Leases	0.7	1.42	1.37	1.95	2.51	2.4
Current Income Taxes Payable	28.68	4.44	26.29	15.47	18.28	5.29
Current Unearned Revenue	2.37	11.38	13.37	5.97	4.5	4.2
Other Current Liabilities	12	59.37	64.01	5.36	9.89	5.84
Total Current Liabilities	205.45	112.88	137.19	95.12	96.6	75.52
Long-Term Leases	-	-	1.42	2.04	5.39	7.91
Long-Term Unearned Revenue	3.45	3.78	0.01	0.01	0.27	1.13
Long-Term Deferred Tax Liabilities	0.2	0.13	0.27	0.44	0.57	0.14
Total Liabilities	209.1	116.79	138.88	97.61	102.83	84.69

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	404.59	404.59	404.59	404.59	343.9	343.9
Additional Paid-In Capital	1,015	1,015	1,015	1,015	102.59	101.69
Retained Earnings	921.1	801.2	660.67	502.12	276.09	116.05
Shareholders' Equity	2,341	2,221	2,080	1,921	722.59	561.65
Total Liabilities & Equity	2,550	2,338	2,219	2,019	825.42	646.34

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.7	1.42	2.78	4	7.91	10.31
Net Cash (Debt)	1,510	1,467	1,431	1,599	368.54	252.12
Net Cash Growth	6.28%	2.56%	-10.52%	333.90%	46.18%	208.59%
Net Cash Per Share	3.77	3.64	3.53	4.53	1.08	0.75
Filing Date Shares Outstanding	404.59	404.59	404.59	404.59	404.59	343.9
Total Common Shares Outstanding	404.59	404.59	404.59	404.59	343.9	343.9
Working Capital	1,590	1,527	1,458	1,621	413.44	268.84
Book Value Per Share	5.79	5.49	5.14	4.75	2.10	1.63
Tangible Book Value	2,255	2,134	2,026	1,903	703.22	541.76
Tangible Book Value Per Share	5.57	5.27	5.01	4.70	2.04	1.58
Buildings	231.94	231.94	231.94	232.54	231.65	163.47
Machinery	112.22	105.34	96.7	87.77	79.06	57.22
Construction In Progress	109.26	58.15	18.07	1.82	5.76	7.17

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 25, 2026

Data Sources Report a data error